TREX1 and neoplasm: Indeed, TREX1 appears to be upregulated in different tumor entities, including cervical, breast, and hepatocellular cancer (34, 35), making TREX1 an attractive target in tumor therapy, whose inactivation is thought to increase cancer cell immunogenicity (36, 37).